Navigation Links
SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment
Date:2/19/2009

- Clinical Performance Indicates a 40% Reduction of Intraocular Pressure at Two Years -

WALTHAM, Mass., Feb. 19 /PRNewswire/ -- SOLX, Inc. announced today that it has surpassed 1000 implantation procedures with its proprietary SOLX Gold Shunt(R), a drainage device that reduces intraocular pressure (IOP) for the treatment of glaucoma.

"This is a significant milestone," said Doug Adams, President and Founder of SOLX, "as it validates the importance of the Gold Shunt in the treatment of glaucoma. The Gold Shunt provides a more reliable, less invasive surgical alternative in IOP control."

The 1000 patients were treated in the European Union where the device has received CE Mark approval. Entering 2009, over 100 glaucoma surgeons in 20 countries have been certified on Gold Shunt implantation. Clinical results have shown that a significant reduction in IOP of 40% can be maintained for over two years after Gold Shunt implantation while also reducing the patient's need for glaucoma medications by up to half.

"Our patients treated with the Gold Shunt achieved a reduction in IOP which was maintained at clinically beneficial levels for an extended time period," said Modi Goldenfeld, M.D. of the Goldschleger Eye Institute in Tel Hashomer, Israel, and Medical Monitor for an ongoing FDA trial. "One particularly attractive feature of the Gold Shunt is that it utilizes a naturally occurring pressure differential found between the anterior chamber of the eye and the suprachoroidal space which allows the device to reduce IOP without creating a bleb, and thus eliminate bleb related complications."

About SOLX

SOLX is an emerging leader in the management and surgical treatment of glaucoma, a disease of the eye characterized by high intraocular pressure that often leads to optic nerve damage, vision loss and ultimately, blindness.

Additional information can be found at www.solx.com


'/>"/>
SOURCE SOLX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology: